ARV-771 NEW
| Price | $55 | $122 | $197 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-03 |
Product Details
| Product Name: ARV-771 | CAS No.: 1949837-12-0 |
| Purity: 99.69% | Supply Ability: 10g |
| Release date: 2025/12/03 |
Product Introduction
Bioactivity
| Name | ARV-771 |
| Description | ARV-771 is an effective BET degrader based on PROTAC technology. The Kd for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1) and BRD4(2) are 34 and 4.7 respectively. , 8.3, 7.6, 9.6 and 7.6 nM. |
| In vitro | METHODS: ARV-771 (0.01/0.025/0.05/0.1/0.25/0.5/1/2μM) was used to culture Hep3B, HepG and HCCLM3 cells to observe whether ARV-771 inhibits the growth of these cancer cells. RESULTS ARV-771 had a dose-dependent inhibition on cancer cell viability when the concentration reached 0.25 μM in Hep3B and HepG2 cells and 0.5 μM in HCCLM3 cells. [1] |
| In vivo | METHODS: Nude mice successfully bearing transplanted HepG2 cell tumors were randomly divided into two groups and treated with ARV-771 (20 mg/kg/day, subcutaneous injection) every other day for 25 days. Tumor volume and body weight of mice were measured every 5 days. Immediately after extraction of xenografts from mice, tumor weight was measured by an electronic balance. RESULTS After ARV-771 treatment, tumor volume and tumor weight were significantly reduced. Immunochemical detection results showed that ARV-771 reduced the expression of Ki67 and increased the expression of cleaved Caspase 3 in xenograft tissues. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.03 mM), Sonication is recommended. DMSO : 10 mM, Sonication is recommended. |
| Keywords | PROTACs | Inhibitor | inhibit | EpigeneticReaderDomain | Epigenetic Reader Domain | BET | ARV-771 | ARV771 | ARV 771 |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | ARV-471 | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin |
| Related Compound Libraries | Preclinical Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/25KG |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-03-31 | |
| $0.00/1mg |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-08-26 | |
| $0.00/100MG |
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 | ||
| $0.00/1mg |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-08-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY